Roche Suspends Elevidys Dosing in Non-Ambulatory DMD Patients Amid Safety Concerns Roche today announced a significant update to its dosing guidelines for Elevidys™ (delandistrogene moxeparvovec), following a careful reassessment of…
Johnson & Johnson’s RedirecTT-1 Study Shows Durable Responses in Heavily Pretreated Multiple Myeloma Patients with Extramedullary Disease Johnson & Johnson today presented new and promising data from its Phase 2…
Elanco’s Zenrelia (ilunocitinib) Wins Positive CVMP Opinion, Paving the Way for EU Approval and Market Release Elanco Animal Health Incorporated (NYSE: ELAN) today announces a significant milestone in its ongoing…
mRNA Technology Transfer Programme Moves Into Phase 2.0, Boosting Sustainable Local Vaccine Manufacturing and Global Health Security In parallel with the G20 Health Working Group meeting, global health leaders and…
Mitsubishi Research Institute and Astellas Forge Collaborative Initiative to Support Japanese Drug Discovery Startups and Boost Global Innovation Mitsubishi Research Institute, Inc. (MRI) and Astellas Pharma Inc. (Astellas) today announced…
Amgen and Barry Sanders Raise Awareness About “Bad Cholesterol” in Documentary Highlighting Cardiovascular Disease Crisis in America Amgen today announced the launch of The Making of a Heart Attack, a…
FDA Approves KEYTRUDA® (Pembrolizumab) for Perioperative Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma Merck known as MSD outside the United States and Canada, recently announced that…
Johnson & Johnson’s Dual-Targeting CAR T-Cell Therapy Shows Encouraging First Clinical Results in Large B-Cell Lymphoma Johnson & Johnson recently presented promising first-in-human data from its ongoing Phase 1b study…
Dapirolizumab Pegol Shows Disease Activity Reduction and Fatigue Improvement in SLE at EULAR 2025 UCB and Biogen today presented additional and detailed results from the Phase 3 PHOENYCS GO study…
Merck Highlights Positive Enpatoran Phase 2 WILLOW Study Data in SLE at EULAR 2025 Merck, a leading science and technology company, today presented new and detailed results from its Phase…
GSK Licenses Shigella Vaccine Candidate to Bharat Biotech in Push for Global Health Equity GSK today announced a significant step forward in the battle against Shigella a leading cause of…
Bristol Myers Squibb Highlights Targeted Protein Degradation Advances, Including CELMoD Agents and BCL6 Ligand-Directed Degrader, at EHA 2025 in Milan, Italy Bristol Myers Squibb today revealed new and updated data…